Pharmacytimes http://www.pharmacytimes.com/rss PharmacyTimes.com offers continuing education (CE) courses, career guidance for pharmacy students, online-only articles, digital versions of the print issue, and more, that are essential to pharmacists en-us Tue, 13 Nov 18 06:45:25 +0000 Tue, 13 Nov 18 06:45:25 +0000 Report Links Hepatitis A Outbreaks in Certain States to Drug Use, Homelessness http://www.pharmacytimes.com/news/report-links-hepatitis-a-outbreaks-in-certain-states-to-drug-use-homelessness http://www.pharmacytimes.com/news/report-links-hepatitis-a-outbreaks-in-certain-states-to-drug-use-homelessness A new report published in the CDC&nbsp;<em>Morbidity and Mortality Weekly Report</em>&nbsp;(MMWR) has linked cases of acute hepatitis A virus (HAV) infections from certain states to person-to-person transmission from drug use or homelessness. &nbsp; Mon, 12 Nov 18 16:17:00 +0000 FDA OKs Keytruda for Treatment of Hepatocellular Carcinoma http://www.pharmacytimes.com/news/fda-oks-keytruda-for-treatment-of-hepatocellular-carcinoma http://www.pharmacytimes.com/news/fda-oks-keytruda-for-treatment-of-hepatocellular-carcinoma The FDA approved Merck&rsquo;s pembrolizumab (Keytruda) for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib. Fri, 09 Nov 18 22:22:00 +0000 Once-Daily Nebulized Therapy for COPD Gets FDA Approval http://www.pharmacytimes.com/news/oncedaily-nebulized-therapy-for-copd-gets-fda-approval http://www.pharmacytimes.com/news/oncedaily-nebulized-therapy-for-copd-gets-fda-approval Revefenacin (Yupelri, Theravance Biopharma and Mylan) is the first once-daily, long-acting nebulized bronchodilator for the treatment of chronic obstructive pulmonary disease.<br /> &nbsp; Fri, 09 Nov 18 21:33:00 +0000 FDA OKs Emergency Use of First Ebola Fingerstick Test with Portable Reader http://www.pharmacytimes.com/news/fda-oks-emergency-use-of-first-ebola-fingerstick-test-with-portable-reader http://www.pharmacytimes.com/news/fda-oks-emergency-use-of-first-ebola-fingerstick-test-with-portable-reader The action will increase access to diagnostic tools for healthcare providers who may not have otherwise been equipped to perform tests. Fri, 09 Nov 18 10:42:00 +0000 Study: Potential Targets Identified for Inhibiting Liver Disease Progression http://www.pharmacytimes.com/news/study-potential-targets-identified-for-inhibiting-liver-disease-progression http://www.pharmacytimes.com/news/study-potential-targets-identified-for-inhibiting-liver-disease-progression Chronic liver disease and cirrhosis can contribute to the development of liver cancer, which affects approximately 33,000 individuals in the United States each year. Wed, 07 Nov 18 14:00:00 +0000 New Immunotherapy Combination Granted FDA Approval for Certain Adults with Multiple Myeloma http://www.pharmacytimes.com/news/new-immunotherapy-combination-granted-fda-approval-for-certain-adults-with-multiple-myeloma http://www.pharmacytimes.com/news/new-immunotherapy-combination-granted-fda-approval-for-certain-adults-with-multiple-myeloma Officials with the FDA have approved elotuzumab (Empliciti) injection for intravenous use in combination with pomalidomide and dexamethasone for the treatment of certain patients with relapsed or refractory multiple myeloma. Tue, 06 Nov 18 22:00:00 +0000 Medication Nonadherence in Older Adults: Patient Engagement Solutions and Pharmacist Impact http://www.pharmacytimes.com/news/medication-nonadherence-in-older-adults-patient-engagement-solutions-and-pharmacist-impact http://www.pharmacytimes.com/news/medication-nonadherence-in-older-adults-patient-engagement-solutions-and-pharmacist-impact Medication nonadherence is a major cause of morbidity, especially in elderly patients. Tue, 06 Nov 18 19:00:00 +0000 Groundbreaking Drug for Treating 2 Rare Forms of Epilepsy Now Available http://www.pharmacytimes.com/news/groundbreaking-drug-for-treating-2-rare-forms-of-epilepsy-now-available http://www.pharmacytimes.com/news/groundbreaking-drug-for-treating-2-rare-forms-of-epilepsy-now-available This cannabidiol oral solution can be prescribed in the United States to treat seizures associated with Dravet or Lennox-Gastaut syndrome. Mon, 05 Nov 18 13:00:00 +0000 FDA Grants Accelerated Approval to Lorlatinib for ALK+ NSCLC http://www.pharmacytimes.com/news/fda-grants-accelerated-approval-to-lorlatinib-for-alk-nsclc http://www.pharmacytimes.com/news/fda-grants-accelerated-approval-to-lorlatinib-for-alk-nsclc The FDA has granted lorlatinib (Lorbrena) an accelerated approval for the treatment of patients with&nbsp;ALK-positive metastatic non&ndash;small cell lung cancer (NSCLC) who have progressed on 1 or more ALK tyrosine kinase inhibitors. Sun, 04 Nov 18 15:00:00 +0000 Higher HPV Vaccination Rate Needed to Combat Cancer http://www.pharmacytimes.com/news/higher-hpv-vaccination-rate-needed-to-combat-cancer http://www.pharmacytimes.com/news/higher-hpv-vaccination-rate-needed-to-combat-cancer Although HPV vaccination rates have steadily increased in recent years, more work is needed in this area to effectively reduce HPV-associated cancer, according to a new report release by the President&rsquo;s Cancer Panel. Sat, 03 Nov 18 14:00:00 +0000 FDA Grants Approval to Biosimilar for Patients Receiving Myelosuppressive Chemotherapy http://www.pharmacytimes.com/news/fda-grants-approval-to-biosimilar-for-patients-receiving-myelosuppressive-chemotherapy http://www.pharmacytimes.com/news/fda-grants-approval-to-biosimilar-for-patients-receiving-myelosuppressive-chemotherapy Officials with the FDA have approved Coherus BioSciences&rsquo; Udenyca&trade; (pegfilgrastim-cbqv) for patients with cancer receiving myelosuppressive chemotherapy.&nbsp;The drug is &nbsp;a biosimilar to Amgen&rsquo;s Neulasta (pegfilgrastim). Fri, 02 Nov 18 20:45:00 +0000 Clobazam Oral Film Granted FDA Approval for Lennox-Gastaut Syndrome http://www.pharmacytimes.com/news/clobazam-oral-film-granted-fda-approval-for-lennoxgastaut-syndrome http://www.pharmacytimes.com/news/clobazam-oral-film-granted-fda-approval-for-lennoxgastaut-syndrome This approval marks the first and only oral film approved by the FDA to treat seizures associated with Lennox-Gastaut syndrome. Fri, 02 Nov 18 15:36:00 +0000 AAD Releases New Guidelines for Melanoma Treatment http://www.pharmacytimes.com/news/aad-releases-new-guidelines-for-melanoma-treatment- http://www.pharmacytimes.com/news/aad-releases-new-guidelines-for-melanoma-treatment- The guidelines also highlight the importance of discussions between health care providers and patients. Fri, 02 Nov 18 04:28:00 +0000 Independent Corner: Towncrest Pharmacy Builds Relationships with Patients and Providers through Clinical Services http://www.pharmacytimes.com/news/independent-corner-towncrest-pharmacy-builds-relationships-with-patients-and-providers-through-clinical-services- http://www.pharmacytimes.com/news/independent-corner-towncrest-pharmacy-builds-relationships-with-patients-and-providers-through-clinical-services- Thu, 01 Nov 18 14:00:00 +0000 23andMe Gets FDA Nod for First DTC Genetic Test for Medication Metabolism http://www.pharmacytimes.com/news/23andme-gets-fda-nod-for-first-dtc-genetic-test-for-medication-metabolism http://www.pharmacytimes.com/news/23andme-gets-fda-nod-for-first-dtc-genetic-test-for-medication-metabolism The test is the first of its kind to secure FDA approval. Thu, 01 Nov 18 02:50:00 +0000 FDA OKs Biosimilar Adalimumab for Autoimmune Conditions http://www.pharmacytimes.com/news/fda-approves-biosimilar-adalimumab-for-autoimmune-conditions http://www.pharmacytimes.com/news/fda-approves-biosimilar-adalimumab-for-autoimmune-conditions The FDA has&nbsp;approved&nbsp;Sandoz&rsquo;s biosimilar adalimumab, Hyrimoz (adalimumab-adaz) for the treatment of&nbsp;rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.&nbsp; Thu, 01 Nov 18 02:01:00 +0000 FDA OKs Pembrolizumab for Squamous NSCLC with Chemotherapy http://www.pharmacytimes.com/news/fda-oks-pembrolizumab-for-squamous-nsclc-with-chemotherapy http://www.pharmacytimes.com/news/fda-oks-pembrolizumab-for-squamous-nsclc-with-chemotherapy The expanded indication marks the first time an anti-PD-1 regimen has been approved in the first-line setting as both combination and monotherapy for squamous NSCLC, regardless of tumor PD-L1 expression status. Wed, 31 Oct 18 14:35:00 +0000 Tips to Stay Healthy on Halloween http://www.pharmacytimes.com/news/tips-to-stay-healthy-on-halloween http://www.pharmacytimes.com/news/tips-to-stay-healthy-on-halloween The CDC offers 7 tips to avoid any health scares this season. Wed, 31 Oct 18 13:00:00 +0000 FDA Moves to Halt Use of Lead Acetate in Hair Dyes http://www.pharmacytimes.com/news/fda-moves-to-halt-use-of-lead-acetate-in-hair-dyes http://www.pharmacytimes.com/news/fda-moves-to-halt-use-of-lead-acetate-in-hair-dyes The action, FDA officials explained in a press release, is based on new data that suggest there is no longer a reasonable certainty that there is no harm from the use of lead acetate as a color additive. Tue, 30 Oct 18 21:12:00 +0000 Combination Therapy Improves Progression-Free Survival for Untreated Kidney Cancer http://www.pharmacytimes.com/news/combination-therapy-improves-progressionfree-survival-for-untreated-kidney-cancer http://www.pharmacytimes.com/news/combination-therapy-improves-progressionfree-survival-for-untreated-kidney-cancer Avelumab, an immune checkpoint inhibitor, in combination with axitinib, a tyrosine kinase inhibitor, significantly improved progression-free survival in untreated renal cell carcinoma. Tue, 30 Oct 18 18:15:00 +0000 Hospitals Honored for Efforts to Eliminate Preventable Deaths http://www.pharmacytimes.com/news/hospitals-honored-for-efforts-to-eliminate-preventable-deaths http://www.pharmacytimes.com/news/hospitals-honored-for-efforts-to-eliminate-preventable-deaths Three hospitals made significant progress in reducing deaths associated with poor quality health care.<br /> &nbsp; Tue, 30 Oct 18 13:53:00 +0000 Drug Receives FDA Approval for Treating Narcolepsy in Pediatric Patients http://www.pharmacytimes.com/news/drug-receives-fda-approval-for-treating-narcolepsy-in-pediatric-patients http://www.pharmacytimes.com/news/drug-receives-fda-approval-for-treating-narcolepsy-in-pediatric-patients Officials with the FDA have approved Jazz Pharmaceuticals&#39; Xyrem (sodium oxybate) for the treatment of cataplexy and excessive daytime sleepiness (EDS) in pediatric patients aged 7 to 17 years with narcolepsy. Sun, 28 Oct 18 14:00:00 +0000 Brown Bag Consult: Caring for Skin http://www.pharmacytimes.com/news/brown-bag-consult-caring-for-skin http://www.pharmacytimes.com/news/brown-bag-consult-caring-for-skin In this series, Jill Drury, PharmD, a clinical pharmacy specialist, provides patients with &quot;Brown Bag&quot; consultations. Patients bring to the pharmacy their current medications and over-the-counter products, giving the pharmacist an additional resource for pharmaceutical counsel. In this video, a patient with fair skin is planning a tropical vacation. She seeks advice about topical skin protection and potential adverse effects from the sun with her medications. Sat, 27 Oct 18 14:00:00 +0000 Drug Treatment for Psoriasis Now Available in United States http://www.pharmacytimes.com/news/drug-treatment-for-psoriasis-now-available-in-united-states http://www.pharmacytimes.com/news/drug-treatment-for-psoriasis-now-available-in-united-states Tildrakizumab-asmn (Ilumya), an injectable interleukin-23 (IL-23) inhibitor, was&nbsp;<a href="https://www.pharmacytimes.com/news/fda-approves-treatment-for-moderatetosevere-psoriasis"><strong>approved by the FDA&nbsp;in March</strong></a> for adults who are candidates for systemic therapy or phototherapy. Fri, 26 Oct 18 14:00:00 +0000 Generic Clobazam Tablets Granted FDA Approval http://www.pharmacytimes.com/news/generic-clobazam-tablets-granted-fda-approval http://www.pharmacytimes.com/news/generic-clobazam-tablets-granted-fda-approval Breckenridge Pharmaceutical&#39;s Clobazam Tablets, CIV, generic for Onfi&reg; Tablets (Lundbeck), has been granted FDA approval&nbsp;for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older. Wed, 24 Oct 18 15:07:00 +0000